Underuse of evidence-based pharmacotherapies for affective disorders

Psychiatric Services

Volumn 54, Issue 8, 2003, Pages 1076-1078

  Dwight Johnson, Megan ^a   Lagomasino, Isabel T ^a   Simpson, George M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NARCOTIC AGENT; NEUROLEPTIC AGENT; SELEGILINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VALPROIC ACID;

ATYPICAL DEPRESSION; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DIET RESTRICTION; EVIDENCE BASED MEDICINE; HUMAN; KIDNEY DISEASE; MAJOR DEPRESSION; MANIA; MELANCHOLIA; MOOD DISORDER; NEUROPATHIC PAIN; PRACTICE GUIDELINE; SHORT SURVEY; SIDE EFFECT; THYROID DISEASE; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HEALTH SERVICES MISUSE; HUMANS; LITHIUM; MONOAMINE OXIDASE INHIBITORS; MOOD DISORDERS; PRACTICE GUIDELINES; SOCIETIES, MEDICAL;

EID: 0042130107     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.54.8.1076     Document Type: Short Survey

References (38)

1. Nemeroff CB: Evolutionary trends in the pharmacotherapeutic management of depression. Journal of Clinical Psychiatry 55 (suppl):3-15, 1994
2. Mitchell PB, Malhi GS: The expanding pharmacopeia for bipolar disorder. Annual Review of Medicine 53:173-188, 2002
3. Sambamoorthi U, Olfson M, Walkup JT, et al: Diffusion of new generation antidepressant treatment among early diagnosed with depression. Medical Care 41:180-194, 2003
4. Jefferson JW: Rediscovering the art of lithium therapy. Current Psychiatry 1(12):18-24, 2002
5. Fieve RR: Lithium therapy at the millennium: a revolutionary drug used for 50 years faces competing options and possible demise. Bipolar Disorders 2:67-70, 1999
6. Blanco C, Laje G, Olfson M, et al: Trends in the treatment of bipolar disorder by outpatient psychiatrists. American Journal of Psychiatry 159:1005-1010, 2002
7. Bauer MS, Callahan AM, Jampala C, et al: Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. Journal of Clinical Psychiatry 60:9-21, 1999
8. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry 159(suppl 4):1-50, 2002
9. Thase ME, Rush AJ: When at first you don't succeed: sequential strategies for antidepressant nonresponders. Journal of Clinical Psychiatry 58(suppl 13):23-29, 1997
10. American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 157(suppl 4):1-45, 2000
11. Anderson IM, Nutt DJ, Deakin JFW: Evidence-based guidelines for treating depressive disorders with antidepressants: revision of the 1993 British Association for Psychopharmacology Guidelines Journal of Psychopharmacology 14:3-20, 2000
12. Liebowitz MR, Quitkin F, Stewart J, et al: Antidepressant specificity in atypical depression. Archives of General Psychiatry 45:129-137, 1988
13. Quitkin F, McGrath PJ, Stewart JW, et al: Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Archives of General Psychiatry 47:935-941, 1990
14. Quitkin F, Harrison WM, Stewart JW, et al: Response to phenelzine and imipramine in placebo nonresponders with atypical depression. Archives of General Psychiatry 48:319-323, 1991
15. McGrath PJ, Stewart JW, Nunes E, et al: A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. American Journal of Psychiatry 150:118-123, 1993.
16. Thase ME, Trivedi MH, Rush AJ: MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12:185-219, 1995
17. Thase ME, Frank E, Mallinger AG, et al: Treatment of imipramine-resistant recurrent depression: III. efficacy of monoamine oxidase inhibitors. Journal of Clinical Psychiatry 53:5-11, 1992
18. Anderson IM: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58:19-36, 2000
19. Roose S, Glassman AH, Attia E, et al: Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry 151:1735-1739, 1994
20. Anderson IM: Meta-analytical studies on new antidepressants. British Medical Bulletin 57:161-178, 2001
21. Garcia J, Altman R: Chronic pain states: pathophysiology and medical therapy. Seminars in Arthritis and Rheumatology 27:1-16, 1997
22. Thase ME, Rush AJ, Howland RH, et al: Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of General Psychiatry 59:233-239, 2002
23. Preskorn SH, Fast GA: Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. Journal of Clinical Psychiatry 52(suppl):23-33, 1991
24. Simon GE, Vonkorff M, Heiligenstein JH, et al: Initial antidepressant choice in primary care-effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 275:1897-1902, 1996
25. Dording CM: Depression: recent developments and innovative treatments. Psychiatric Clinics of North America 23:743-755, 2000
26. Burgess S, Geddes J, Hawton K, et al: Lithium for maintenance treatment of mood disorders. Cochrane Library, issue 1, 2003
27. Macritchie KAN, Geddes JR, Scott J, et al: Valproic acid, valproate, and dicalproex in the maintenance treatment of bipolar disorder. Cochrane Library, issue 1, 2003
28. Baldessarini RJ, Tondo L, Hennen J: Lithium treatment and suicide risk in major affective disorders: update and new findings. Journal of Clinical Psychiatry 64(suppl 5): 44-52, 2003
29. Conney J, Kaston B: Pharmacoeconomic and health outcome comparison of lithium and divalproex in a VA geriatric nursing home population: influence of drug-related morbidity on total cost of treatment. American Journal of Managed Care 5:197-204, 1999
30. Keck PE Jr, Nabulsi AA, Taylor LJ, et al: A pharmacoeconomic model of divalproex vs lithium in the acute and prophylactic treatment of bipolar I disorder. Journal of Clinical Psychiatry 57:213-222, 1996
31. Bauer M, Dopfmer S: Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. Journal of Clinical Psychopharmacology 19:4 27-434, 1999
32. Sclar DA, Robinson LM, Skaer TL, et al: Trends in the prescribing of antidepressant pharmacotherapy: office-based visits, 1990-1995. Clinical Therapeutics 20:871-884, 1998
33. Robinson D: Monoamine: oxidase inhibitors: a new generation. Psychopharmacology Bulletin 36:124-138, 2002
34. Olfson M, Marcus SC, Pincus HA, et al: Antidepressant prescribing practices of outpatient psychiatrists. Archives of General Psychiatry 55:310-316, 1998
35. McManus P, Mant A, Mitchell P, et al: Recent trends in the use of antidepressant drugs in Australia, 1990-1998. Medical Journal of Australia 173:458-461, 2000
36. Petersen T, Dording CM, Neault NB, et al: A survey of prescribing practices in the treatment of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26:177-187, 2002
37. Mischoulon D, Nierenberg AA, Kizilbash L, et al: Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Canadian Journal of Psychiatry 45:476-481, 2000
38. Janicak PG, Davis JM, Preskorn SH, et al: Principles and Practice of Psychopharmacotherapy. Baltimore, Williams & Wilkins, 1993